High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas
2012 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas
Schrader, A.; Bentink, S.; Spang, R.; Lenze, D.; Hummel, M.; Kuo, M. & Arrand, J. R. et al. (2012)
International Journal of Cancer, 131(4) pp. E348-E361. DOI: https://doi.org/10.1002/ijc.26423
Documents & Media
Details
- Authors
- Schrader, Alexandra; Bentink, Stefan; Spang, Rainer; Lenze, Dido; Hummel, Michael; Kuo, Michael; Arrand, John R.; Murray, Paul G.; Truemper, Lorenz H.; Kube, Dieter; Vockerodt, Martina
- Abstract
- Gene expression profiling has recently enabled the reclassification of aggressive non-Hodgkin lymphomas (aNHL) into distinct subgroups. In Burkitt lymphoma (BL) aberrant c-Myc activity results from IG-MYC translocations. However, MYC aberrations are not limited to BLs and then have a negative prognostic impact. In this study, we investigated to which extent aberrant c-Myc activity plays a functional role in other aNHL and whether it is independent from MYC translocations. Based on a combined microarray analysis of human germinal center (GC) B cells transfected with c-Myc and 220 aNHLs cases, we developed a c-Myc index. This index measures the extent to which lymphomas express c-Myc responsive genes. It comprises genes that are affected in a variety of tumors compared to normal tissue. This supports the view that aberrant c-Myc expression in GC B cells triggers a tumor-like expression pattern. As expected, the c-Myc index is very high in molecular Burkitt lymphoma (mBL), but more importantly also high within other aNHL. It constitutes a negative prognostic marker independent of established risk factors and of the presence of a MYC translocation. Our data provide new insights into the role of c-Myc activity in different lymphomas and raises the question of treatment changes for those patients under risk.
- Issue Date
- 2012
- Status
- published
- Publisher
- Wiley-blackwell
- Journal
- International Journal of Cancer
- ISSN
- 0020-7136